Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicorandil for exercise endurance in HFpEF with coronary microcirculation dysfunction
ChiCTR2200067078Phase 4Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of nicorandil in heart failure with preserved ejection fraction (HFpEF) and Coronary Small Vessel Disease (CMD) (2 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Improvement in exercise endurance. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
nicorandil
03
Conditions
heart failure with preserved ejection fraction (HFpEF)Coronary Small Vessel Disease (CMD)
Beyond the preview
Go deeper on ChiCTR2200067078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067078.